Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Yayoi Ando und 15 weiteren Autor:innen. Beteiligte Einrichtung: Research Management Division, Clinical Research Support Office, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Neoplasm Recurrence, Local, Organometallic Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Previously, we conducted the phase I study of 64Cu-ATSM, which is Cu-diacetyl-bis (N4-methylthiosemicarbazone) radiolabeled with Cu-64, for patients with brain tumors and determined the maximum tolerated dose. We started a subsequent multicenter, randomized, open-label phase III study to evaluate the efficacy of 64Cu-ATSM as an investigator-initiated registration-directed trial for recurrent or residual malignant glioma (protocol No. NCCH2301, STEP-64). Patients will be randomized to either the control or study arm (64Cu-ATSM). A large-scale randomized trial seems difficult to perform for patients with brain tumors because of small sample sizes. Therefore, we designed a small randomized trial with 56 patients. Furthermore, as a pragmatic approach in the control arm, physicians can choose treatments depending on the patient’s condition among the clinically available options, where the drugs used are not regarded as investigational. The trial was registered in the Japan Registry of Clinical Trials as jRCT2031240090.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Management Division, Clinical Research Support Office, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
- Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
- Department of Diagnostic Radiology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-ku, Yokohama-city, Kanagawa 241-8515, Japan.
- Department of Diagnostic Radiology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
- Data Management Division, Clinical Research Support Office, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
- Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Japan.
ORCID-Profile: Yayoi Ando, Makoto Ohno, Yoshitaka Narita
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Ando, Y., Yanagisawa, S., Ohno, M., Kurihara, H., Ito, K., Ichimura, M., Anjo, K., Inaba, M., Nagasaka, Y., Sadachi, R., Shibata, T., Okita, N., Nakamura, K., Matsumoto, H., Yoshii, Y., & Narita, Y. (2025). Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf026
Vancouver
Ando Y, Yanagisawa S, Ohno M, Kurihara H, Ito K, Ichimura M, et al. Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf026
BibTeX
@article{Ando2025,
author = {Ando, Yayoi and Yanagisawa, Shunsuke and Ohno, Makoto and Kurihara, Hiroaki and Ito, Kimiteru and Ichimura, Masahiko and Anjo, Kenta and Inaba, Masako and Nagasaka, Yukari and Sadachi, Ryo and Shibata, Taro and Okita, Natsuko and Nakamura, Kenichi and Matsumoto, Hiroki and Yoshii, Yukie and Narita, Yoshitaka},
title = {Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf026}
}
EUVIMED